NLNatalie Loundon

Natalie Loundon

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Natalie Loundon has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hearing Outcomes in Functional Surgery for Middle Ear Malformations

    by Daniel Philippon, Nathalie Laflamme, Nicolas Leboulanger, Natalie Loundon, Isabelle Rouillon, Erea-Noel Garabedian, Francoise Denoyelle

    To standardize the information for families of children having functional surgery for middle ear malformations, we describe the audiometric results of the subgroup of patients with the most favorable anatomic conditions: viable auditory canal, intact tympanic membrane, mobile stapes, and corresponding to a Jahrsdoerfer score of 8 or higher. Case series, tertiary referral center. Charts of patients undergoing functional surgery for congenital middle ear malformations were reviewed for demographic data, preoperative Jahrsdoerfer score, ossicular chain status, type of ossiculoplasty, and audiometric data before and 6 months postsurgery. Eighteen consecutive interventions were performed on 13 patients (average age of 9 years, 8 girls and 5 boys) between 2004 and 2011. The ossiculoplasties performed were as follows: incus repositioning (4), double-layer tragal cartilage (5), intact native chain reconstruction (3), and partial ossicular prosthesis (6). Mean air bone gap (ABG) was 40.8 ± 12.4 dB preoperatively and 20.9 ± 12.9 dB postoperatively (p < 0.0001). Preoperative and postoperatively mean air conduction PTA thresholds were 49.9 ± 9.5 and 30.0 ± 14.1 dB, respectively (p < 0.0001). All ears operated on except one had air conduction improvement. There were no complications. Functional surgery for congenital middle ear malformations gives variable hearing outcomes. In this study, with the most favorable anatomic conditions, 12 ears (67%) of 18 had air conduction improvement below 30 dB.


  • Congenital Cytomegalovirus Is the Second Most Frequent Cause of Bilateral Hearing Loss in Young French Children

    by Véronique Avettand-Fenoël, Sandrine Marlin, Christelle Vauloup-Fellous, Natalie Loundon, Martine François, Vincent Couloigner, Isabelle Rouillon, Valérie Drouin-Garraud, Laurence Laccourreye, Françoise Denoyelle, et al.

    In children with congenital cytomegalovirus (cCMV), greater than 50% of symptomatic newborns and 8.5% to 18% of asymptomatic newborns will have hearing loss, either present at birth or delayed in onset. This prospective study was undertaken to evaluate the extent of cCMV among causes of hearing loss in French children younger than 3 years and to assess their characteristics in relation to cCMV status. Children younger than 3 years with hearing loss were prospectively enrolled. Cytomegalovirus polymerase chain reaction (PCR) assays were performed on dried blood spots from these children’s Guthrie cards and considered positive when CMV presence was confirmed. Brain computed tomography (CT) or magnetic resonance imaging and temporal bone CT scans were obtained. Normal hearing, mild loss, moderate loss, severe loss, and profound loss were defined when the child was able to hear a stimulus of 0 to 20, 21 to 40, 41 to 70, 71 to 90, and 91 dB or greater, respectively. Results of genetic analysis of the connexin 26 (GJB2) and connexin 30 (GJB2) genes were recorded. The prevalence of cCMV infection was estimated together with its 95% confidence interval. Of 114 eligible children, 100 with bilateral hearing loss were enrolled at a median age of 15 months and included in the analysis. Hearing loss in the best ear was not recorded for 2 children and was mild in 1 child, moderate in 22 children, severe in 16, and profound in 59. Results of brain and temporal bone imaging were available for 77 children and genetic analysis of the GJB2 and GJB2 genes for 55 children. Cytomegalovirus PCR was positive in 8 children, and cCMV infection prevalence was 8.0% (95% confidence interval, 2.7%–13.3%). Prevalence of cCMV was 13.7% (n = 8) in the 59 children with profound bilateral hearing loss, a significant association (P = 0.02). Children with cCMV were significantly more likely to have delayed development (P = 0.027) and abnormalities on the brain CT scan (P = 0.0005). Two of the 8 children with cCMV had at least 1 other risk factor for hearing loss, including neonatal intensive care unit stays or familial history of hearing loss. None of the 8 children with cCMV were born prematurely, but 4 had a small birth weight for their gestational age, and 1 child had microcephaly. In 2 children, the diagnosis of cCMV infection had been made before inclusion in the study. For the other 6 children, the diagnosis of cCMV was made retrospectively because of the positive CMV PCR result. In 61 patients (71.8%), the origin of hearing loss was genetic. Mutations of GJB2 and/or GJB2 genes were found in 22 patients (25.9%). In 1 patient (1.2%), hearing loss was due to a mutation in the otoferlin gene. In 13 patients (15.3%), a syndromic origin included Waardenburg syndrome, Usher syndrome, Angelman disease, mucopolysaccharidosis, and another metabolic disease. In 8 patients (9.4%), a malformation was found in the temporal bone on CT scan that was considered genetic. A genetic origin also was highly probable in 10 with a history of 1 family member with hearing loss before age 40 years and consanguineous parents in 7. Prematurity was the cause of hearing loss in 6 children (7.1%). Congenital CMV was present in 8 (9.4%) of the 85 patients with a complete workup and was the second most common individual cause of bilateral hearing loss after connexin mutations. The prevalence of cCMV indicates only the proportion of cCMV among French children with bilateral hearing loss and not the prevalence of cCMV in the total population of children with hearing loss. Because universal neonatal hearing screening is underway in France, it may be possible to diagnose cCMV in infants with confirmed hearing loss and to implement early intervention with antiviral treatment.

  • Benefits from upgrade to the CP810™ sound processor for Nucleus® 24 cochlear implant recipients

    by Isabelle Mosnier, Mathieu Marx, Frederic Venail, Natalie Loundon, Samantha Roux-Vaillard, Olivier Sterkers

    The objective of this study was to measure performance benefits obtained by upgrading recipients of the Cochlear™ Nucleus® CI24 cochlear implant to the new CP810™ sound processor. Speech recognition in quiet and in spatially separated noise was measured in established users of the Cochlear ESPrit 3G™ (n = 22) and Freedom™ (n = 13) sound processors, using the “Everyday” listening program. Subjects were then upgraded to the CP810 processor and were re-assessed after a 3-month period, using both the “Everyday” program and the new “Noise” program, which incorporates several pre-processing features including a new directional microphone algorithm (“Zoom™”). Subjective perceptions were also recorded using the abbreviated profile of hearing aid benefit (APHAB) questionnaire. Mean scores for monosyllables in quiet, presented at 50 and 60 dB SPL, increased by 11 % (p < 0.0001) and 8 % (p < 0.001), respectively, after upgrade, for all subjects combined. Significant increases were also recorded for both processor groups. In noise, the mean scores were 60.0 and 67.4 % for the original and CP810 Everyday programs, respectively (difference not significant). With the CP810 Noise programs the mean score increased to 82.5 % (p < 0.01), with significant increases in both processor groups. There was evidence of slightly greater upgrade benefit in users of the ESPrit 3G processor and in relatively poor performers. The APHAB questionnaire also indicated significant reduction in perceived difficulty in the background noise and reverberation sub-scales after upgrade. The findings of the study appear to support the expectation of increased benefit from the new CP810 sound processor.


  • New Closed Skin Bone-Anchored Implant

    by Françoise Denoyelle, Nicolas Leboulanger, Cyrille Coudert, Olivia Mazzaschi, Natalie Loundon, Eric Vicaut, Natacha Tessier, Eréa-Noël Garabedian

    Objective To report preliminary results of a new closed-skin, transcutaneous bone conduction device (BCD) in 6 children with high-grade ear atresia Settings Tertiary care center; prospective study; we evaluated the gain with masking of the contralateral ear and the benefit of hearing rehabilitation with the transcutaneous BCD in noise: speech-in-noise tests, conducted in real life condition (with contralateral ear unmasked and fitted with a hearing device if done before implantation), with and without BCD, with determination of the speech reception threshold (SRT). Children and parent’s satisfaction was assessed. Results Patients’ ages ranged from 6 to 9 years. All had high-grade ear atresia with a preoperative mean pure-tone average (PTA) loss of 71.46 ± 6.59 dB on air conduction and 14 ± 4.98 dB on bone conduction. At M6, all children used the implant 5 to 12 hours daily (mean, 10) without pain or cutaneous complications. At M6, the mean air conduction PTA with transcutaneous BCD was 28.45 ± 1.68 dB, the mean gain 43 ± 6.96 dB, and the mean SRT gain 33.33 ± 10.75 dB. Using speech-in-noise tests in real-life conditions, the mean SRT was statistically improved with the transcutaneous BCD (−8 ± 2.83 dB, p = 0.0313). Both children and parents reported being satisfied or very satisfied. Conclusion These preliminary results show satisfactory functional gain, cutaneous tolerance, and patients’ satisfaction with the new transcutaneous BCD.


  • Cochlear Implantation and Congenital Deafness

    by Wissame El Bakkouri, Natalie Loundon, Briac Thierry, Jerome Nevoux, Sandrine Marlin, Isabelle Rouillon, Erea Noel Garabédian

    Objective: To evaluate the perceptive and linguistic results in 2 predefined genetic population of children with implants. Study Design: Retrospective cohort study. Setting: Otolaryngology department of a tertiary referral hospital. Patients Among 336 children with prelingual deafness who underwent implantation in our department between 1997 and 2007, 85 with GJB2 gene-related (Cx) deafness and 30 patients with Waardenburg syndrome (WaardS) were included. Mean age at implantation was 4.7 years (range, 15 mo to 16.5 yr) in the Cx group and 4.8 years (range, 16 mo to 16 yr) in the WaardS group. The mean follow-up period was 6.5 years (range, 19 mo to 12 yr) in the Cx group and 7.1 years (range, 27 mo to 13.5 yr) in the WaardS group. More than 75% of the families in both groups scored 4 and 5 when using the Mary Pat Moeller rating (p > 0.05). A psychoneurological evaluation was performed in one third of the patients in both groups. Main Outcome Measures Patients underwent linguistic and perceptive evaluations at 12, 24, 36, and 48 months: speech perception with closed-set and open-set words, speech production (Level 1 = vocalizations to Level 5 = complex sentences), and lexical comprehension with EVIP/GaelP (Peabody Picture Vocabulary Test) tests that ranged in 5 levels (−2 SD to +2 SD). Results Score results for open-set words were 38.5%, 57.5%, 69%, and 75% in the Cx group and 30.5%, 59%, 67.5%, and 78% in the WaardS group (p > 0.05) at 12, 24, 36, and 48 months. The proportion of children in Levels 4 and 5 of speech production was 27%, 42%, 57.5%, and 58% in the Cx group and 23%, 33%, 55%, and 66% in the WaardS group (p > 0.05). Lexical result at Level −2 SD at 1 year was 90% in the Cx group and 85% in the WaardS group and that at 4 years was 70% in the Cx group and 65% in the WaardS group (p > 0.05). Conclusion Perceptive and linguistic evolutions for both populations were of good quality, but lexical evaluation showed residual language difficulties in both groups.


  • Medical and Surgical Complications in Paediatric Cochlear Implantation

    by Natalie Loundon, Marion Blanchard, Gilles Roger, Françoise Denoyelle, Erea Noël Garabedian


  • Open Access

    Medical and Surgical Complications in Pediatric Cochlear Implantation

    by Natalie Loundon, Marion Blanchard, Gilles Roger, Françoise Denoyelle, Erea Noël Garabedian

    The success of cochlear implantation (CI) as an auditory rehabilitative tool requires a thorough knowledge of indications, limitations, and potential risks. Since 1990, the number of pediatric CIs has increased significantly, and more specific pediatric evaluation of the medical and surgical risks can be collected. This study reports on the complications occurring in a pediatric population and analyzes the predisposing risk factors.


  • Open Access

    GJB2 and GJB6 Mutations

    by Sandrine Marlin, Delphine Feldmann, Hélène Blons, Natalie Loundon, Isabelle Rouillon, Sébastien Albert, Pierre Chauvin, Eréa-Noël Garabédian, Rémy Couderc, Sylvie Odent, et al.

    Hearing loss is the most frequent sensory deficit. One child in 1000 is born with severe or profound deafness, and another 1 in 1000 becomes deaf before adulthood. Recent work in human genetics indicates that 60% to 80% of cases of congenital deafness are of genetic origin in developed countries1 and that nonsyndromic sensorineural hearing loss (NSSNHL) is mainly autosomal recessive. Since 1994, more than 80 loci for NSSNHL have been identified, and 35 different genes have been cloned.1 Despite extensive genetic heterogeneity, a single locus on chromosome band 13q12 has been recognized to account for a large proportion of cases of nonsyndromic autosomal recessive deafness (DFNB1). Furthermore, the gene that encodes connexin 26, GJB2, has been identified as causative in DFNB1.1 The GJB2 gene is also involved in an autosomal dominant form of deafness, DFNA3, and in syndromes such as Vohwinkel or keratitis-ichtyosis-deafness syndrome. The GJB6 gene, which encodes connexin 30, maps close to GJB2. The GJB6 gene was first described as causative in a rare dominant form of deafness, DFNA3, and its implication in NSSNHL was ascertained through the identification of a large deletion that includes the GJB6 5′-end noncoding region and most of the coding region. This genetic alteration was found in patients with hearing impairment who carry a GJB2 mutation in trans and at a homozygous state in some families.2-4 In those patients, it is still not clear whether the deafness is due to a digenic pattern of inheritance or whether the deletion removes common GJB6 and GJB2 regulatory elements.5